Gut Microbiome Disruption Following SARS-CoV-2: A Review
Elda Righi(Ospedale Santa Maria della Misericordia di Udine), Assunta Sartor(University of Udine), Concetta Sciammarella(Inserm), Elisa Gentilotti(University of Verona), Lorenza Lambertenghi(University of Verona), Evelina Tacconelli(University of Verona), Matteo Morra(University of Verona), Nina Auerbach(University of Verona), Ilaria Dalla Vecchia(University of Verona), Massimo Mirandola(University of Verona), Anna Górska(University of Verona)
Cited by 19
Related Papers
The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
|The Lancet Infectious Diseases|2025|526
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study
|Clinical Infectious Diseases|2020|155
Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis
|Journal of Antimicrobial Chemotherapy|2016|114